NaPi2b: a viable solid tumor target for novel ADC technologies – a pipeline review

STUTTGART, Germany I September 04, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-NaPi2b immunotherapies in R&D: Pipeline of NaPi2b-Targeted Immunotherapies.

This competitive intelligence report about NaPi2b-Targeted Immunotherapies provides an up-to-date competitor evaluation in the field of product candidates in research and development targeting NaPi2b. This report will be prepared on demand within one working day upon order placement. The report lists active NaPi2b-targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of NaPi2b-targeted therapies by drug modality. The report will be provided in pdf format and sent by e-mail to the customer.

As an example of this category of on demand reports, please see our free sample report of “Pipeline of 5T4-Targeted Immunotherapies”.

NaPi2b, encoded by the SLC34A2 gene, is a cell surface multi-transmembrane, sodium-dependent phosphate transporter with an antibody-accessible extracellular loop, that regulates sodium-dependent phosphate homeostasis. Functionally, it is involved in trans-cellular flux of phosphate in the small intestine and in the synthesis of surfactant in lung alveoli. NaPi2b is reported to be expressed at a high frequency in ovarian carcinoma as well as in NSCLC, bladder, endometrial and papillary thyroid carcinoma, and its expression is associated with poor prognosis. NaPi2b is highly expressed in certain cancers, e.g. in 75 to 90% of both non-squamous NSCLC and epithelial ovarian cancer, but with limited expression in normal tissues, making it a promising target for antibody-drug conjugates (ADCs).

Development of first-generation NaPi2b-targeted ADCs using auristatin as payload (upifitamab rilsodotin, lifastuzumab vedotin) was discontinued opening the way for next generation safer and more effective ADCs.

The report “Pipeline of NaPi2b-Targeted Immunotherapies” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/pipeline-of-napi2b-targeted-immunotherapies/

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.

La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, customized reports about target evaluation, pipeline analysis, technology assessments, drug and competitor profiles, partnering and business deal terms and any other competitive intelligence elaboration of interest.

Among La Merie Publishing’s services are the pre-scoped evaluation of customer-selected targets for drug discovery: Target Evaluation for Drug Discovery: Pre-Scoped Premium Evaluation and the pre-scoped review of the pipeline of immunotherapies against customer-selected targets: Pipeline Review of Customer-Selected Targeted Immunotherapies: Pre-Scoped Competitor Analysis.

SOURCE: La Merie Publishing